Madrigal Pharmaceuticals Has Completed The Rolling Submission Of Its New Drug Application To The FDA For Resmetirom For NASH With Liver Fibrosis; Madrigal Has Requested A Priority Review Of The Resmetirom Application
Portfolio Pulse from Benzinga Newsdesk
Madrigal Pharmaceuticals has completed the rolling submission of its New Drug Application (NDA) to the FDA for Resmetirom, a treatment for NASH with liver fibrosis. The company has requested a priority review of the application.

July 17, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Madrigal Pharmaceuticals' completion of the NDA submission for Resmetirom could potentially expedite the drug's approval process, which may positively impact the company's stock in the short term.
The completion of the NDA submission is a significant step towards the potential approval of Resmetirom. If the FDA grants a priority review, the review process could be expedited, potentially leading to earlier-than-expected revenues from the drug. This could positively impact Madrigal's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100